Related Experiment Video
Updated: Jun 8, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.2K
Insulin Resistance Is a Modifying Factor for Parkinson's Disease
Alise Zagare1, Ahmed Hemedan2, Catarina Almeida1,3
1Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Summary
Insulin resistance in the brain contributes to Parkinson's disease (PD) pathogenesis, particularly in GBA-PD. Targeting FOXO1 or using Pioglitazone may protect against neuron loss.
Area of Science:
- Neuroscience
- Genetics
- Metabolism
Background:
- Parkinson's disease (PD) is a rapidly growing neurodegenerative disorder with largely unknown causes.
- Identifying non-genetic risk factors is key for developing effective PD treatments.
- Central insulin resistance is increasingly implicated in PD, but its origin and brain-specific role remain unclear.
Purpose of the Study:
- Investigate the role of insulin resistance in GBA1 mutation-associated Parkinson's disease (GBA-PD).
- Examine the impact of insulin resistance on GBA-PD pathogenesis and disease severity.
Main Methods:
- Generated midbrain organoids from induced pluripotent stem cells (iPSCs) of GBA-PD patients and healthy donors.
- Manipulated insulin signaling in organoids and performed transcriptomics analysis.
- Assessed gene expression patterns and identified potential therapeutic targets.
Main Results:
- Observed dysregulation of insulin signaling pathway genes in GBA-PD.
- Demonstrated that reducing FOXO1 expression mitigates dopaminergic neuron loss and cell death in GBA-PD.
- Identified Pioglitazone as a potential therapeutic agent to decrease dopaminergic neuron loss in GBA-PD.
Conclusions:
- Local insulin signaling dysfunction significantly contributes to GBA-PD pathogenesis.
- Insulin resistance exacerbates dopaminergic neuron death in GBA-PD.
- Targeting insulin signaling pathways offers potential therapeutic strategies for GBA-PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
01:15Parkinson's Disease: Overview
483
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
483
01:36Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175
01:16Insulin: Dosing Regimen and Adverse Effects
146
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
146
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K